Systemic lupus erythematosus candidate genes in the Italian population: Evidence for a significant association with interleukin-10

Arthritis and Rheumatism

Volumn 43, Issue 1, 2000, Pages 120-128

  D'Alfonso, Sandra ^a   Rampi, Marco ^a   Bocchio, Daniela ^a   Colombo, Gualtiero ^b   Scorza Smeraldi, Raffaella ^b   Momigliano Richiardi, Patricia ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLIPIN ANTIBODY; FC RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PROTEIN BCL 2; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; ITALY; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMOTER REGION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIGENS, CD; ANTIGENS, CD19; ANTIGENS, DIFFERENTIATION; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOCONJUGATES; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-10; ITALY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, IGG; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS;

EID: 0034121689     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200001)43:1<120::AID-ANR15>3.0.CO;2-3     Document Type: Article

References (56)

1. Deapen D, Escalante A, Weinrib L, Horwitz D, Bachman B, Roy-Burman P, et al. A revised estimate of twin concordance in systemic lupus erythematosus. Arthritis Rheum 1992;35:311-8.
2. Arnett FC. The genetic basis of lupus erythematosus. In: Wallace DJ, Hahn BH, editors. Dubois' lupus erythematosus. 4th ed. Philadelphia: Lea and Febiger; 1993. p 13-36.
3. Mountz JD, Wu J, Cheng J, Zhou T. Autoimmune disease: a problem of defective apoptosis. Arthritis Rheum 1994;37:1415-20.
4. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 1995;16:39-43.
5. Zhou T, Edwards CK III, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996;156:2661-5.
6. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced Bcl-2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci U S A 1991;88:8661-5.
7. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959-62.
8. Komata T, Tsuchiya N, Matsushita M, Hagiwara K, Tokunaga K. Association of tumor necrosis factor receptor 2 (TNFRII) polymorphism with susceptibility with systemic lupus erythematosus. Tissue Antigens 1999;53:527-33.
9. Korsmeyer SJ. Bcl-2: a repressor of lymphocyte death. Immunol Today 1992;13:285-8.
10. Mehrian R, Quismorio FP Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, et al. Synergistic effect between IL-10 and bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum 1998;41:596-602.
11. Komaki S, Kohno M, Matsuura N, Shimadzu M, Adachi N, Hoshide R, et al. The polymorphic 43Thr bcl-2 protein confers relative resistance to autoimmunity: an analytical evaluation. Hum Genet 1998;103:435-40.
12. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50.
13. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995;270:985-8.
14. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7.
15. Nisticò L, Buzzetti R, Pritchard LE, van der Auwera B, Giovannini C, Bosi E, et al. The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes: Belgian Diabetes Registry. Hum Mol Genet 1996;5:1075-80.
16. Yanagawa T, Hidaka Y, Guimaraes V, Soliman M, DeGroot LJ. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J Clin Endocrinol Metab 1995;80:41-5.
17. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994;56:1-26.
18. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
19. Rousset F, Garcia E, Defrance T, Peronne C, Vezzio N, Hsu DH, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci U S A 1992;89:1890-3.
20. Levy Y, Brouet JC. Interleukin-10 prevents spontaneous death of germinal center B cells by induction of the bcl-2 protein. J Clin Invest 1994;93:424-8.
21. Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10.
22. Eskdale J, Wordsworth P, Bowman S, Field M, Gallagher G. Association between polymorphisms at the human IL-10 locus and systemic lupus erythematosus. Tissue Antigens 1997;49:635-9.
23. Tedder TF, Inaoki M, Sato S. The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity 1997;6:107-18.
24. Van der Pol WL, van de Winkel JGJ. IgG receptor polymorphisms: risk factors for disease. Immunogenetics 1998;48:222-32.
25. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJ. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43.
26. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, et al. Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 1996;97:1348-54.
27. Duits AJ, Bootsma H, Derksen RHWM, Spronk PE, Kater L, Kallenberg CGM, et al. Skewed distribution of IgG Fc receptor IIa (CD32) polymorphism is associated with renal disease in systemic lupus erythematosus patients. Arthritis Rheum 1995;38:1832-6.
28. Song YW, Han C-W, Kang S-W, Back H-J, Lee E-B, Shin C-H, et al. Abnormal distribution of Fcγ receptor type IIa polymorphisms in Korean patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:421-6.
29. Botto M, Theodoridis E, Thompson EM, Beynon HL, Briggs D, Isenberg DA, et al. Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin Exp Immunol 1996;104:264-8.
30. Manger K, Repp R, Spriewald BM, Rascu A, Geiger A, Wassmuth R, et al. Fcγ receptor IIa polymorphism in Caucasian patients with systemic lupus erythematosus: association with clinical symptoms. Arthritis Rheum 1998;41:1181-9.
31. Smyth LJ, Snowden N, Carthy D, Papasteriades C, Hajeer A, Ollier WE. Fc gamma RIIa polymorphism in systemic lupus erythematosus. Ann Rheum Dis 1997;56:744-6.
32. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol 1998;16:457-99.
33. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380-5.
34. Suzuki H, Matsui Y, Kashiwagi H. Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:389-90.
35. Danis VA, Millington M, Huang Q, Hyland V, Grennan D. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and systemic lupus erythematosus. Dis Markers 1995;12:135-9.
36. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
37. D'Alfonso S, Colombo G, Della Bella S, Scorza R, Momigliano-Richiardi P. Association between polymorphisms in the TNF region and systemic lupus erythematosus in the Italian population. Tissue Antigens 1996;47:551-5.
38. Tanaka S, Kant J, Reed JC. G to A polymorphism in the second exon of the BCL-2 gene. Nucleic Acids Res 1991;19:1964.
39. Sham PC, Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann Hum Genet 1995;59:97-105.
40. Kruglyak L. Genetic isolates: separate but equal? Proc Natl Acad Sci U S A 1999;96:1170-2.
41. Llorente L, Zou W, Levy Y. Richaud-Patin Y, Wijdenes J, Alcocer-Varela J, et al. Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus. J Exp Med 1995;181:839-44.
42. Llorente L, Richaud-Patin Y, Fior R, Alcocer-Varela J, Wijdenes J, Fourrier BM, et al. In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjögren's syndrome, and systemic lupus erythematosus: a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 1994; 37:1647-55.
43. Hagiwara E, Gourley MF, Lee S, Klinman DM. Disease severity in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10:interferon-γ-secreting cells in the peripheral blood. Arthritis Rheum 1996;39:379-85.
44. Kono DH, Burlingame RW, Owens DG, Kuramochi A, Balderas RS, Balomenos D, et al. Lupus susceptibility loci in New Zealand mice. Proc Natl Acad Sci U S A 1994;91:10168-72.
45. Drake CG, Rozzo SJ, Vyse TJ, Palmer E, Kotzin B. Genetic contributions to lupus-like disease in (NZB xNZW)F1 mice. Immunol Rev 1995;144:51-74.
46. Drake CG, Rozzo SJ, Hirschfeld HF, Smarnworawong NP, Palmer E, Kotzin BL. Analysis of the New Zealand Black contribution to lupus-like renal disease: multiple genes that operate in a threshold manner. J Immunol 1995;154:2441-7.
47. Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A 1998;95:14869-74.
48. Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malmgren ML. et al. A genome-wide search for susceptibility genes in human systemic lupus crythcmatosus sib-pair families. Proc Natl Acad Sci U S A 1998;95:14875-9.
49. Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 1999;8:639-44.
50. Tsao BP, Cantor RM, Kalunian KC, Chen CJ, Badsha H, Singh R, et al. Evidence for linkage of a candidate chromosome 1 region to human systemic lupus erythematosus. J Clin Invest 1997;99:725-31.
51. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997;349:170-3.
52. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci U S A 1998;95:9465-70.
53. Mok CC, Lanchbury JS, Chan DW, Lau CS. Interleukin-10 promoter polymorphisms in Southern Chinese patients with systemic lupus erythematosus. Arthritis Rheum 1998;41: 1090-5.
54. Lazarus M, Hajeer AH, Turner D, Sinnott P, Worthington J, Ollier WER, et al. Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. J Rheumatol 1997; 24:2314-7.
55. Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, et al. Physical mapping and genomic structure of the human TNFR2 gene. Genomics 1996;35:94-100.
56. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun 1999;1:3-19.